Leptospira contamination – How to manage risk
27th September 2012
Category: Biosafety
Tags: Leptospira contamination, Vaccines
By: Dr Daniel Galbraith, CSO,
Vaccines and Biologics are recognized to be at high risk of contamination by bacteria and viruses. Over many years the risks have been determined and these products are recognized to be among the safest on the market. In the past there have been a number of viral contamination events which have resulted in increased vigilance and additional testing for “in process” and final product tests. Recently, the announcement from Genentech that there was contamination by Leptospira sp. in two bioreactors has highlighted where potentially the testing paradigms may fail. Leptospira is an unusual organism in many respects but importantly can remain silent in all of the current tests used to identify contamination. In the Genentech incidents there were no live microbes present in the final product however there remains the possibility that this organism can contaminate batches of product and may be a risk to patients in the future.
There are a number of testing methods which can be used to identify Leptospira the method of choice will require to be sensitive and fast to report, clearly nucleic amplification techniques are ideal in this respect.
BioOutsource is pleased to announce the introduction of a sensitive PCR assay to detect Leptospira for our clients. The assay can be used to detect Leptospira contamination in cell banks as well as in process and final vialed product. From sample receipt to reporting results can be performed in 48 hours.
Related Articles
What is Sterility Testing? During the production of biopharmaceuticals, contaminating microorganisms can enter the process at many stages. Once introduced, bacteria or fungi can replicate exponentially, severely compromising the final product. The presence of microorganisms in vaccines and other biopharmaceuticals can over time both spoil the product and pose a major risk to patient health. More
Biosafety Testing from Cell Line Development Through to Lot Release For the release of biopharmaceutical drugs onto the market, products must be shown to be safe. Regulatory bodies such as the US Food & Drug Administrators (FDA) and the Medicines and Healthcare Regulatory Agency (MHRA) require products are tested for compliance before release. This involves a More
In April of 1983 while on a late-night Friday “moonlit drive through the mountains of California” to his weekend cabin in Mendocino, Kary Mullis, a researcher at the Cetus Corporation biotechnology company, experienced a “Eureka” moment that would change the world forever (1). The idea made him stop the car on the side of the highway More
Human cytomegaloviruses (and simian) are members of a virus family that are specifically identified by the biologics safety guidelines as a specific concern. Most recently the 2010 FDA guidelines for testing of vaccine cell substrate included a recommendation that if there is the possibility of contamination with Human and Simian cytomegalovirus then the in vitro More
The risk of contamination of biopharmaceuticals and vaccines by Bovine viruses has been well recognized. Calf serum was, and in some instances still is, commonly used to supplement the growth media for cells used in production of many vaccines and some biologics. Although “serum-free” media is frequently used today the risk of exposure to bovine More
